How many employees does Neovacs have this year?
Neovacs has 24 undefined employees this year.
Neovacs Employees 2024
Neovacs Employees
24
Ticker
ALNEV.PA
ISIN
FR0004032746
WKN
A1CVKR
In 2024, Neovacs employed 24 people, a 0% change from the 24 number of employees in the previous year.
Neovacs Aktienanalyse
What does Neovacs do?
Neovacs SA is a French biotechnology company specializing in the development of immunotherapies for the treatment of autoimmune diseases and cancer. It was founded in 1993 by Pierre Vandepapeliere and is headquartered in Paris. The company has a history of groundbreaking discoveries and continuous innovation. Its business model is based on the combination of cutting-edge research and the development of customized therapies for the treatment of autoimmune diseases and cancer. Neovacs SA identifies specific proteins that trigger an immune response against the body's own cells and tissues, and develops Kinoid vaccines to neutralize these proteins and stop the autoimmune reaction. It is also specialized in the development of immunotherapies for the treatment of cancer. The main divisions of Neovacs SA are clinical development, regulatory affairs, and the manufacturing of Kinoid vaccines. It has achieved an impressive track record in the clinical development of Kinoid vaccines and collaborates with leading universities, hospitals, and research institutions to support its research and development activities. The company currently offers a range of different Kinoid vaccines for the treatment of autoimmune diseases, including a product for the treatment of lupus, a product for the treatment of rheumatoid arthritis, and a product for the treatment of chronic hepatitis B. All of these products are currently in Phase 2 development. Another important product being developed by Neovacs SA is an immunotherapeutic for the treatment of cancer. Known as TNF-Kinoid, the product aims to enhance the body's immune defense against cancer cells and inhibit tumor growth. It has shown promising results in Phase 1 clinical development and is currently in Phase 2 development. Neovacs SA is a strong and growing company in a rapidly evolving sector of biotechnology. It has an impressive track record in the clinical development of immunotherapies for the treatment of autoimmune diseases and cancer, and is well-positioned to continue making significant contributions to healthcare. Neovacs ist eines der beliebtesten Unternehmen auf Eulerpool.com.Employees Details
Examining Neovacs's Employee Base
Neovacs's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Neovacs's operational capacity and future potential.
Year-to-Year Comparison
Assessing Neovacs's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.
Impact on Investments
Neovacs's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.
Interpreting Employee Trends
Fluctuations in Neovacs’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.
Frequently Asked Questions about Neovacs stock
How many employees did Neovacs have compared to the previous year?
Compared to the previous year, Neovacs had 0% more employees.
What impact did the number of employees have on the company Neovacs?
The number of employees has a direct impact on the efficiency and productivity of Neovacs. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.
What impact did the number of employees have on investors of Neovacs?
The number of employees can also have an impact on investors of Neovacs, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.
How does an increase in equity capital of Neovacs affect the company?
An increase in equity of Neovacs can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.
How does a reduction in Neovacs's equity affect the company?
A reduction in equity of Neovacs can impair its financial stability and decrease its ability to fulfill future investments and obligations.
What are some factors that influence the equity of Neovacs?
Some factors that can influence the equity of Neovacs include, among others, revenue development, profit and loss statement, dividend payments, and investments.
Why is the equity of Neovacs so important for investors?
The equity of Neovacs is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.
How does the number of employees at Neovacs influence the company?
The number of employees at Neovacs can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.
How has the number of employees at Neovacs evolved in recent years?
In recent years, the number of employees at Neovacs has changed by 0.
How many employees does Neovacs currently have?
Neovacs currently has 24 undefined employees.
Why is the number of employees important for investors of Neovacs?
The number of employees is important for investors of Neovacs as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.
What strategic measures can Neovacs take to change the number of employees?
To change the number of employees, Neovacs can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.
How much dividend does Neovacs pay?
Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.
What is the dividend yield of Neovacs?
The current dividend yield of Neovacs is .
When does Neovacs pay dividends?
Neovacs pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neovacs?
Neovacs paid dividends every year for the past 0 years.
What is the dividend of Neovacs?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neovacs located?
Neovacs is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neovacs from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Neovacs pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Neovacs in the year 2023?
In the year 2023, Neovacs distributed 0 EUR as dividends.
In which currency does Neovacs pay out the dividend?
The dividends of Neovacs are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neovacs
Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
